- Phase 3 since 12 Oct 2011: CSL Limited’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov.
- Next primary completion: 6 May 2029, the registry's estimate, of NCT07048262 (phase 2) — when its main measure’s data collection ends, not when results are announced.study pageClinicalTrials.gov ↗
- One program: TAK339Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: CSL787Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: TAK881Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: GC5107Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: NPB01Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: BAY411000Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- Evidence: NCT00389324: “Immune Globulin Intravenous (Human)” (other names: Gamunex, Gaminex, Immune globulin intravenous (Human)(IGIV), BAY 41-1000, TAL-05-00004, IGIV-C, IVIG, IGIVnex, NDC-13353-645-71, NDC-13353-646-24, NDC-13353-645-12, NDC-13353-645-15, NDC-13353-645-2)study pageClinicalTrials.gov ↗record history ↗
- One program: TAL0500004Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- Evidence: NCT00389324: “Immune Globulin Intravenous (Human)” (other names: Gamunex, Gaminex, Immune globulin intravenous (Human)(IGIV), BAY 41-1000, TAL-05-00004, IGIV-C, IVIG, IGIVnex, NDC-13353-645-71, NDC-13353-646-24, NDC-13353-645-12, NDC-13353-645-15, NDC-13353-645-2)study pageClinicalTrials.gov ↗record history ↗
- One program: GB0998Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- Kept apart: KIG10Judged by our rule (version d2907d7): two different drugs in our concepts · 2026-11-14
- Kept apart: IGPRO20Judged by our rule (version d2907d7): two different drugs in our concepts · 2026-11-14
- Kept apart: another drug record (INT016614)Judged by our rule (version d2907d7): two different drugs in our concepts · 2026-11-14
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Johnson & Johnson leads of it also tests nipocalimab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Sanofi leads of it also tests riliprubart, Rituximab or biosimilar.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Emergent BioSolutions leads of it also tests Anthrax Immune Globulin Intravenous.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Annexon, Inc. leads of it also tests tanruprubart.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Novartis leads of it also tests tesidolumab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 24 companies; each of the 1 studies Laboratoire français de Fractionnement et de Biotechnologies leads of it also tests Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL).
- Kept apart: another drug record (INT007650)Judged by our rule (version d2907d7): two different drugs in our concepts · 2026-11-14
|